Contentious debate follows report on higher oncology drug prices at safety-net hospitals
A report suggesting that safety-net hospitals are charging 3.8 times more for oncology drugs has sparked pushback from hospitals,
By Scott Wooldridge|September 24, 2021 at 09:49 AM
Thank you for sharing!
Your article was successfully shared with the contacts you provided.
A report finding that safety-net hospitals are charging 3.8 times more than the purchase price for oncology drugs has sparked pushback from hospitals, which say the report had too small a sample size and did not accurately reflect costs to consumers.
The initial report, by the nonprofit Community Oncology Alliance (COA), noted that the federal system of reporting requirements is complex and evolving—regulators have proposed and enacted a range of price transparency rules for hospitals in recent years, with data-gathering and compliance still problematic in many cases. And the report acknowledges that these safety-net hospitals (known as 340B hospitals) serve a poorer, less-insured population and face competitive challenges.
Complete your profile to continue reading and get FREE access to BenefitsPRO.com, part of your ALM digital membership.
Your access to unlimited BenefitsPRO.com content isn’t changing. Once you are an ALM digital member, you’ll receive:
Critical BenefitsPRO.com information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events.
Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com